Notwithstanding recent COVID-19 relief legislation overhauling the US Food and Drug Administration’s OTC drug review program, studies go on to support GRASE decision-making for six antiseptic drug ingredients hitherto subject to deferred FDA rulemaking.
“We’re proceeding for the time being,” said the American Cleaning Institute’s James Kim, vice president of science and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?